Zoryl MV 1 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 1mg, Metformin 500mg, and Voglibose 0.2mg, formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to enhance insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and improves peripheral insulin sensitivity, contributing to better glucose uptake and utilization. Voglibose, an alpha-glucosidase inhibitor, delays carbohydrate absorption from the intestine, minimizing postprandial hyperglycemia. The sustained-release (SR) formulation ensures gradual drug release, promoting stable plasma concentrations and improved patient compliance through once-daily dosing. Zoryl MV 1 Tablet SR is indicated for patients inadequately controlled on diet and exercise alone or those requiring combination therapy to achieve optimal glycemic targets. It should be used with caution in patients with renal or hepatic impairment and monitored for potential adverse effects such as hypoglycemia, gastrointestinal disturbances, and lactic acidosis. Regular blood glucose monitoring and periodic assessment of renal function are recommended during therapy. This combination therapy offers a multifaceted approach to managing hyperglycemia, addressing fasting and postprandial glucose levels effectively.